{"id":"W2137551916","doi":"10.1158/1078-0432.ccr-05-2215","title":"Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma","year":2006,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":192,"is_retracted":false,"has_abstract":true,"ca_institutions":"Immunovaccine (Canada)","funders":"National Center for Research Resources; National Institute of Neurological Disorders and Stroke; National Cancer Institute","keywords":"Gefitinib; Medicine; Sirolimus; Rash; Mucositis; Pharmacology; Dosing; Internal medicine; Glioma; Chemotherapy; Tyrosine-kinase inhibitor; Anaplastic astrocytoma; Epidermal growth factor receptor; Oncology; Gastroenterology; Cancer; Cancer research; Astrocytoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001632039,0.0001526651,0.0006572788,0.0002956674,0.00004640212,0.00001476749,0.0001433599,0.0001430379,0.000242074],"category_scores_gemma":[0.0003796297,0.000100441,0.0001662963,0.0007543366,0.0003757278,0.00003669622,0.00007287351,0.0005212441,0.00002592965],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002484433,"about_ca_system_score_gemma":0.0006885635,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003026193,"about_ca_topic_score_gemma":0.001389334,"domain_scores_codex":[0.9967474,0.0003113458,0.0009089896,0.0005197136,0.0009711973,0.00054137],"domain_scores_gemma":[0.997911,0.0008783145,0.000133588,0.0004514406,0.0003884459,0.0002371688],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7805529,0.03965206,0.05425608,0.0005353065,0.000189527,0.003748346,0.0001913842,0.00002633551,0.0007955694,0.0006001347,0.007809061,0.1116433],"study_design_scores_gemma":[0.8693859,0.04717301,0.06530416,0.002889789,0.0001281184,0.00003386504,0.0001855727,0.0003726301,0.00743151,0.0002996446,0.00652868,0.0002670952],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9928904,0.001832334,0.000001172405,0.001803991,0.0001974773,0.001795631,0.00005953884,0.00001610107,0.001403418],"genre_scores_gemma":[0.997658,0.0007633423,0.0000821549,0.00003679856,0.000650624,0.0006572409,0.00003990301,0.00002477873,0.00008717504],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1113762,"threshold_uncertainty_score":0.4574719,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1872098037025844,"score_gpt":0.5209507669304803,"score_spread":0.3337409632278959,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}